Home » Newsletters » BioWorld Science

BioWorld Science

May 17, 2004

View Archived Issues

Sanofi-Synthelabo updates first quarter progress

Antitumor effects of second-generation immunomodulatory oligonucleotides

Gilead's HIV franchise continues to move forward

BioTie highlights developments during interim period

Salix continued progress during first three months of 2004

Seattle Genetics achieves significant milestones during first quarter

Fluoxetine reported to increase systemic exposure to ramelteon

Potential use of antidepressants in patients with IBS

AstraZeneca reports new, highly potent iNOS inhibitors

Nuvelo restarts phase IIa trial with rNAPc2

Roche and Syrrx to develop drugs for cancer and diabetes

Viragen and University of Miami advance cancer study

InKine completes enrollment in phase II study of INKP-102

NovaRx receives new SBIR grant from NIH

Millennium begins phase II trial of Velcade-rituximab combination therapy

Juvaris and SomaGenics enter collaboration for combination product

InterMune begins phase II trial of Infergen/Actimmune combination therapy

Novogen commences phase Ia trial with anticancer drug NV-18

Active Biotech and Avidex collaboration to create potent anticancer agents

European Commission broadens Ferriprox indication

FDA advisory panel recommends rejection of Genasense NDA

Axcan to begin phase III clinical trials with Itax

GlycoGenesys begins phase I trial with GCS-100LE

Spotlight on duloxetine in depression and diabetic neuropathic pain

Efalizumab: Efficacy, safety and effects on quality of life in psoriasis

Memory presents new alpha7 nAChR agonists and their therapeutic use

BMS scientists describe new chemokine CCR3 ligands for asthma and other disorders

Novel SERMs prepared and tested by Lilly researchers

Merck patent covers pyrimidine-based cannabinoid CB1 antagonists/inverse agonists

New PI3K-gamma inhibitors discovered by Bayer scientists

New anti-hepatitis B virus agents claimed by LG Life Sciences

Oral simvastatin treatment against relapsing-remitting multiple sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...